Stabilization of Chronic Lymphatic Leukemia with Amanita phalloides: Effect of Additional Chelidonium majus. Case Report
Isolde Riede *
Independent Cancer Research, Im Amann 7, Ueberlingen, D-88662, Germany.
*Author to whom correspondence should be addressed.
Abstract
Objectives: Amanita phalloides contains amanitin, inhibiting RNA polymerase II. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. A patient with diagnosed B-cell chronic lymphatic leukemia was treated successfully for eight years with Amanita phalloides. However, the necessary dose for stabilization of the disease increased during this time. In addition thrombocyte levels decreased, indicating bone marrow affection. Therefore additional regimen was necessary.
Methods: Chelidonium majus contains alkaloids with cytostatic and cytotoxic potential. In addition to Amanita, Chelidonium was applied.
Results: During treatment with Amanita and Chelidonium, leukocyte levels and lactate-dehydrogenase levels were roughly unaffected, meaning there is no strong effect on tumor growth of cells, and no observable cell destruction. Anyhow, thrombocyte levels increased after the Chelidonium treatment, indicating an effect in the bone marrow.
Conclusion: Chelidonium majus can be useful during Amanita therapy as a pulse to regenerate bone marrow affection.
Keywords: Amanita phalloides, Chelidonium majus, CLL